lncRNA-NKILA/NF-κB feedback loop modulates laryngeal cancer cell proliferation, invasion, and radioresistance

Area of Science:

• Oncology
• Molecular Biology
• Radiotherapy Research

Background:

• Laryngeal cancer is a common malignancy often resistant to radiotherapy.
• NF-κB interacting lncRNA (NKILA) functions as a tumor suppressor by inhibiting NF-κB activation.
• Understanding NKILA's role in laryngeal cancer is crucial for improving treatment outcomes.

Purpose of the Study:

• To investigate the expression levels and prognostic significance of NKILA in laryngeal cancer.
• To elucidate the mechanism by which NKILA influences laryngeal cancer cell behavior and radiosensitivity.
• To explore NKILA as a potential therapeutic target for overcoming radioresistance.

Main Methods:

• Quantitative analysis of NKILA expression in laryngeal cancer tissues.
• Correlation analysis between NKILA levels and patient overall survival.
• In vitro studies assessing the effects of NKILA modulation on cancer cell viability, migration, and apoptosis.
• Investigation of NKILA's interaction with the NF-κB signaling pathway components (IκB, p65) and its role in radiosensitization.

Main Results:

• NKILA expression was significantly lower in laryngeal cancer tissues compared to normal tissues.
• Low NKILA expression correlated with shorter overall survival in laryngeal cancer patients.
• NKILA suppressed laryngeal cancer cell viability and migration while promoting apoptosis.
• NKILA knockdown reversed the radiosensitizing effect of X-ray radiation by inhibiting the NF-κB pathway.
• A negative feedback loop exists where NF-κB activates NKILA transcription, and NKILA subsequently inhibits NF-κB activation.

Conclusions:

• NKILA acts as a tumor suppressor in laryngeal cancer.
• NKILA sensitizes laryngeal cancer cells to X-ray radiation by inhibiting the NF-κB pathway.
• NKILA represents a promising therapeutic target for enhancing radiotherapy efficacy and overcoming radioresistance in laryngeal cancer.